Authors
Erin Guest, John Kairalla, Meenakshi Devidas, Emily Hibbitts, Andrew J Carroll, Nyla A Heerema, Holly Kubaney, Amanda August, Melinda Pauly, Daniel Wechsler, Rodney R Miles, Joel M Reid, Cynthia Kihei, Lia Gore, Elizabeth A Raetz, Stephen P Hunger, Mignon L Loh, Patrick A Brown
Publication date
2022/11/15
Journal
Blood
Volume
140
Issue
Supplement 1
Pages
3256-3257
Publisher
American Society of Hematology
Description
Methods
The Children's Oncology Group (COG) trial AALL15P1 (NCT02828358) was a single arm, open label, groupwide pilot trial. The primary aim of the trial was to evaluate the tolerability of azacitidine in addition to Interfant-06 standard chemotherapy in infants with newly diagnosed KMT2A-r ALL. Estimation of 5-year EFS was an exploratory aim, given the small sample size. Eligibility criteria included B-ALL or acute leukemia of ambiguous lineage with≥ 50% B-lymphoblasts,< 366 days of age at diagnosis, and> 36 weeks gestational age at enrollment. Exclusions included Down syndrome, secondary ALL, and prior cytotoxic therapy (except intrathecal chemotherapy or corticosteroids). Following an Interfant-based induction, infants with KMT2A-r received 4 courses of azacitidine, 2.5 mg/kg/dose intravenously over 10-40 minutes daily for 5 consecutive days in each course, immediately preceding the start of a …
Total citations
Scholar articles
E Guest, J Kairalla, M Devidas, E Hibbitts, AJ Carroll… - Blood, 2022